Telomir Pharmaceuticals, Inc. - Common Stock (TELO)
1.7250
-0.1350 (-7.26%)
NASDAQ · Last Trade: Jun 18th, 1:46 PM EDT
Detailed Quote
Previous Close
1.860
Open
1.970
Bid
1.720
Ask
1.730
Day's Range
1.710 - 1.970
52 Week Range
1.850 - 8.400
Volume
125,884
Market Cap
-
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
245,290
Chart
About Telomir Pharmaceuticals, Inc. - Common Stock (TELO)
Telomir Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies that target cellular aging and age-related diseases. The company specializes in the research and development of medications aimed at enhancing telomere function, which plays a crucial role in cellular health and longevity. By leveraging advanced scientific insights, Telomir Pharmaceuticals aims to transform the treatment landscape for conditions such as cancer and degenerative diseases, ultimately striving to improve the quality of life for patients by addressing the underlying mechanisms of aging. Read More
Telomir Pharmaceuticals (NASDAQ: TELO) announced new preclinical data demonstrating that its lead candidate, Telomir-1, prevented cellular aging in human progeria cell lines obtained from the Progeria Research Foundation. In studies conducted by Smart Assays, Telomir-1 improved cell viability, reduced oxidative stress, and restored mitochondrial function in cells from a child with Hutchinson-Gilford Progeria Syndrome (HGPS), an ultra-rare pediatric aging disorder. Unlike the only FDA-approved treatment, which modestly extends lifespan without reversing disease pathology, Telomir-1 targets key mechanisms of progeria at the molecular level. The results build on previous animal studies and mark a significant step as the company advances IND-enabling work and prepares for potential orphan drug designation.
Telomir Pharmaceuticals (NASDAQ: TELO) announced new preclinical data showing its lead candidate, Telomir-1, significantly reversed neurological, liver, and kidney symptoms in a genetic animal model of Wilson’s disease, a rare disorder caused by copper accumulation. In zebrafish mimicking human pathology, Telomir-1 delivered a 4- to 5-fold reduction in tremors, normalized movement behaviors, cut liver copper levels by 50%, improved organ histopathology, and restored key liver biomarkers to wild-type levels. The drug also improved survival under copper stress, supporting its copper-regulating mechanism. Telomir plans to file its first IND by year-end and begin human trials in 2026.
Telomir Pharmaceuticals (NASDAQ: TELO) announced new preclinical results showing that its lead candidate, Telomir-1, significantly reverses multiple aging markers in a zebrafish model of Werner Syndrome, a rare disorder mimicking accelerated human aging. The orally administered compound extended telomere length by threefold, restored muscle mass and body weight, reduced oxidative stress, and reversed age-related DNA methylation loss. Treated animals also showed a survival benefit compared to controls. CEO Erez Aminov described the findings as a potential milestone in aging science, reinforcing the company’s commitment to advancing Telomir-1 toward human clinical trials.
Telomir Pharmaceuticals (NASDAQ: TELO) announced its participation in the BIO International Convention 2025, taking place June 16–19 in Boston, where it will engage in BIO One-on-One Partnering to explore licensing, M&A, and strategic collaborations. The company is preparing to submit an IND application by year-end for its lead candidate, Telomir-1, a small molecule designed to elongate telomeres and reverse core aging mechanisms. Preclinical data highlight broad therapeutic potential across rare diseases such as Progeria, Werner’s syndrome, and Wilson’s disease, as well as conditions including Type 2 diabetes, aggressive prostate cancer, and macular degeneration. Telomir expects to initiate first-in-human dosing in the first half of 2026 and is seeking FDA guidance on novel clinical endpoints to support accelerated development pathways.
Company to meet with prospective partners as it accelerates toward IND submission for Telomir-1, with plans to begin human dosing in the first half of 2026
Let's have a look at what is happening on the US markets before the opening bell on Monday. Below you can find the top gainers and losers in today's pre-market session.
Telomir Pharmaceuticals (NASDAQ: TELO) announced positive preclinical results demonstrating that its oral therapeutic candidate, Telomir-1, restored vision and reversed retinal degeneration in a genetically modified zebrafish model of age-related macular degeneration (“AMD”). In a 14-day study, Telomir-1 improved central vision response, restored retinal architecture across multiple critical layers, reduced oxidative stress by up to 50%, and eliminated mortality observed in untreated animals. The treated zebrafish showed full recovery of visual function and structural regeneration, including in the inner nuclear and ganglion cell layers, underscoring Telomir-1’s potential as a regenerative treatment for AMD.
A unique oral drug candidate that is shown to restore vision and regenerate the retina in an animal model, addressing a major unmet need in ocular therapeutics
Telomir Pharmaceuticals (NASDAQ: TELO) announced a $3 million equity investment from The Bayshore Trust, the company’s largest shareholder, through the purchase of 1 million restricted shares at $3.00 each—an 18% premium to the stock’s prior closing price. The raise brings total equity investment from affiliated entities to $4 million, complemented by an undrawn $5 million non-dilutive credit line. CEO Erez Aminov emphasized the company’s commitment to shareholder-friendly financing with no warrants or toxic structures. Telomir is advancing two key drug candidates: Telomir-1, a first-in-class age-reversal molecule with broad therapeutic potential, and Telomir-Ag2, a stabilized Silver(II) compound targeting drug-resistant infections. An IND submission for Telomir-1 is planned by year-end, with a focus on rare disease indications to demonstrate early efficacy.
Investment from largest shareholder strengthens balance sheet, signals insider conviction, and funds Telomir-1's upcoming IND submission for a rare disease indication
Telomir Pharma (NASDAQ: TELO) secured $3M in equity financing from Bayshore Trust, its largest shareholder, at $3 per share (18% premium). It also has a $5M credit line. It has 2 innovative drug candidates targeting aging and infections, with promising preclinical results.
Telomir Pharmaceuticals (NASDAQ: TELO) announced the identification of Telomir-Ag2, a stabilized Silver(II) complex demonstrating potent, broad-spectrum antimicrobial activity, including against drug-resistant MARSA. Developed using the company’s proprietary Telomir-1 platform, Telomir-Ag2 is the first Silver(II) compound to achieve biological compatibility, outperforming its Silver(I) predecessor in preclinical studies. Designed for use in high-risk infections such as burns and surgical wounds, the drug candidate targets the growing $1.36 billion silver wound care market and $33.7 billion antimicrobial coatings market. Telomir plans to advance Telomir-Ag2 into IND-enabling studies and explore strategic partnerships.
Antimicrobial resistance is recognized as one of the top global public health threats, and Telomir-Ag2 strengthens Telomir's pipeline with a differentiated candidate designed to address this urgent and expanding crisis
Telomir Pharmaceuticals (NASDAQ: TELO) has released new preclinical data showing its lead oral candidate, Telomir-1, reverses key markers of cellular decline in human cell lines, including improved mitochondrial activity, reduced oxidative stress, and restored calcium balance. The findings underpin Telomir’s expansion into autism spectrum disorder (ASD) and spasmodic dysphonia (SD), both of which share biological disruptions targeted by Telomir-1. The company also plans to engage with the FDA’s Rare Disease Endpoint Advancement Pilot Program to accelerate development in rare conditions like progeria and Wilson’s disease.
MIAMI, FLORIDA / ACCESS Newswire / May 7, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir"), a leader in age-reversal science, today announced new preclinical data showing that its lead oral drug candidate, Telomir-1, reverses multiple hallmarks of cellular decline across several human cell lines. The findings include improved mitochondrial activity, reduced oxidative stress, restored calcium balance, and protection from toxic metal effects-offering a mechanistic foundation for the Company's new research initiatives in autism spectrum disorder (ASD) and spasmodic dysphonia (SD).
Telomir Pharmaceuticals (NASDAQ: TELO) announced preclinical findings showing that its telomere-elongating drug, Telomir-1, reduced tumor size by approximately 50% in a prostate cancer animal model. The study demonstrated that Telomir-1 actively suppresses cancer growth while protecting against chemotherapy-induced toxicity when combined with Paclitaxel. Contrary to concerns that telomere-elongating drugs may promote cancer, Telomir-1 selectively benefited healthy cells while inhibiting tumor development. The company is advancing Telomir-1 toward clinical development for oncology and age-related diseases, aiming to submit an Investigational New Drug (IND) application by the end of 2025.
Telomir-1 shows potential in oncology and age-related diseases, with new findings on its role in tumor suppression and chemotherapy toxicity reduction.
